CINECA IRIS Institutional Research Information System

LOUPAKIS, FOTIOS
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.123
EU - Europa 1.510
AS - Asia 691
AF - Africa 114
SA - Sud America 8
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 7.457
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.033
IT - Italia 314
CN - Cina 297
SE - Svezia 284
DE - Germania 240
BG - Bulgaria 215
SG - Singapore 194
GB - Regno Unito 132
VN - Vietnam 118
CA - Canada 89
CI - Costa d'Avorio 61
FI - Finlandia 58
AT - Austria 57
FR - Francia 48
RU - Federazione Russa 45
HK - Hong Kong 39
SN - Senegal 27
NG - Nigeria 24
ES - Italia 22
UA - Ucraina 17
IN - India 14
NL - Olanda 14
PL - Polonia 10
BE - Belgio 9
CL - Cile 7
CZ - Repubblica Ceca 6
JP - Giappone 6
TR - Turchia 6
CH - Svizzera 5
IL - Israele 5
NO - Norvegia 5
PT - Portogallo 5
EU - Europa 4
LT - Lituania 4
NZ - Nuova Zelanda 4
TW - Taiwan 4
AU - Australia 3
IE - Irlanda 3
RO - Romania 3
SI - Slovenia 3
DK - Danimarca 2
EE - Estonia 2
KR - Corea 2
MT - Malta 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
BA - Bosnia-Erzegovina 1
BR - Brasile 1
BS - Bahamas 1
HU - Ungheria 1
IR - Iran 1
LB - Libano 1
LU - Lussemburgo 1
MY - Malesia 1
RE - Reunion 1
SA - Arabia Saudita 1
TN - Tunisia 1
Totale 7.457
Salva come PNG Salva come JPEG
Città #
Woodbridge 848
Fairfield 695
Houston 532
Ann Arbor 474
Seattle 315
Chandler 306
Ashburn 302
Cambridge 250
Wilmington 241
Sofia 215
New York 142
Beijing 129
Princeton 96
Lawrence 90
Ottawa 76
Des Moines 72
Medford 65
Abidjan 61
Dearborn 57
Vienna 57
Singapore 53
Florence 47
Lancaster 43
Nanjing 40
Pisa 38
Serra 35
Hong Kong 32
Dong Ket 31
Düsseldorf 31
San Diego 30
London 28
Bremen 27
Dakar 27
Lagos 24
Redwood City 23
Ogden 22
Frankfurt am Main 20
Positano 19
Changsha 15
Kunming 15
Boulder 14
Nanchang 14
Seacroft 14
Shenyang 14
Marseille 12
Phoenix 12
Hebei 11
Hefei 10
Rome 9
Boardman 8
Valencia 8
San Francisco 7
Warsaw 7
Brussels 6
Chicago 6
Concepcion 6
Detroit 6
Grafing 6
Liverpool 6
Madrid 6
Milan 6
Shanghai 6
Toronto 6
Indiana 5
Jacksonville 5
Carrara 4
Council Bluffs 4
Dallas 4
Dunedin 4
Izmir 4
Lusciano 4
Oslo 4
San Giuliano Terme 4
Tianjin 4
Bologna 3
Cheltenham 3
Cislago 3
Falls Church 3
Jinan 3
Kilburn 3
Lappeenranta 3
Montreal 3
Norwalk 3
Nürnberg 3
Redmond 3
Rishon Le Zion 3
Rotterdam 3
Vilnius 3
Barcelona 2
Bayreuth 2
Bielefeld 2
Capannori 2
Center 2
Central 2
Dresden 2
Fuzhou 2
Genova 2
Guangzhou 2
Helsinki 2
Hyderabad 2
Totale 5.935
Salva come PNG Salva come JPEG
Nome #
European Guide on Quality Improvement in Comprehensive Cancer Control 196
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 153
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer 146
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers 144
TAS-102 for the treatment of metastatic colorectal cancer 131
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 130
null 129
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 118
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 118
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 117
Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients 113
null 111
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 111
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 110
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 109
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 108
Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. 106
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer 106
BRAF-mutated metastatic colorectal cancer between past and future 105
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials 103
Folfoxiri plus bevacizumab as first-line treatment in braf mutant metastatic colorectal cancer. 103
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 102
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 99
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 99
null 98
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 98
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy 98
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 96
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest 95
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 93
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab 93
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 92
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 92
null 90
Polymorphisms in genes involved in EGFR turnover are predictive for cetuximab efficacy in colorectal cancer 90
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study. 89
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients. 88
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 88
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer 87
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 87
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer 86
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 86
null 85
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis 83
null 83
Single-agent panitumumab in frail elderly patients with advanced RAS and BRAF wild-type colorectal cancer: Challenging drug label to light up new hope 82
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 81
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study 80
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 80
Clinical significance of tlr1 i602s polymorphism for patients with metastatic colorectal cancer treated with folfiri plus bevacizumab 79
prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. 78
Body mass index is prognostic in metastatic colorectal cancer: Pooled analysis of patients from first-line clinical trials in the ARCAD database 77
Quantitative evidence for early metastatic seeding in colorectal cancer 77
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients 75
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 and TRIBE trials 74
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 74
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. 73
null 73
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib 73
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer 73
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 73
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial 72
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib 71
null 69
null 68
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 68
Upfront chemotherapy regimens in unresectable disease: one, two, or three cytotoxics? 66
null 65
Da Vinci Xi Full Robotic Colorectal Resections with Other Major Oncological Surgical Procedures: Preliminary Experience 64
null 62
Phase II study of single-agent cetuximab in KRAS g13d mutant metastatic colorectal cancer 61
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy 61
null 60
Adjuvant sistemy chemotherapy after putative curative resection of colorectal liver and lung metastases. 59
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer 59
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer 59
Folfoxiri and bevacizumab for metastatic colorectal cancer. 55
Pharmacogenomics of cetuximab in metastatic colorectal cancer. 53
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 51
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer (CRC) 46
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 46
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab 43
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study 42
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer. 38
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer 37
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 36
Pharmacogentic concerns in metastatic colorectal cancer therapy. 30
Epstein-Barr virus associated gastric dysplasia: a new rare entity? 30
BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection 29
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis 28
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy 26
Quantitative evidence for early metastatic seeding in colorectal cancer 26
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 24
Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis 18
FIRST EXPERIENCE IN COLORECTAL SURGERY WITH THE NEW INTEGRATED TABLE MOTION FOR THE DA VINCI XI SURGICAL SYSTEM 18
A perspective on the current management of advanced colorectal cancer 15
First-line chemotherapy for mCRC-a review and evidence-based algorithm 15
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer 11
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 10
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. 9
Totale 7.686
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.311
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.311
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.765 196 134 47 141 212 233 193 162 167 142 108 30
2020/2021723 58 49 40 38 38 34 41 41 137 49 54 144
2021/2022937 19 53 16 37 171 152 22 31 59 75 33 269
2022/20231.107 124 166 80 101 112 147 16 57 221 4 76 3
2023/2024640 49 46 96 7 103 103 51 23 17 6 52 87
2024/20255 5 0 0 0 0 0 0 0 0 0 0 0
Totale 7.714